Q3 2024 Talphera Inc Earnings Call Transcript

Nov 13, 2024 / 09:30 PM GMT

Release Date Price: $0.89 (-2.20%)

Transcript 10-Q8-K

Key Points

Positve

Talphera Inc (TLPH) has successfully onboarded five active clinical trial sites with plans to expand to seven by the end of the year, indicating progress in their ongoing registrational trial.
The company is implementing innovative strategies to improve patient enrollment, such as automated text notifications and report generations from electronic medical records.
Talphera Inc (TLPH) has a clear regulatory path with a product candidate that has breakthrough designation from the FDA, which provides quick review and response times.
The company has a strong track record of safety and efficacy for their product, Nafamostat, which has been used as an anticoagulant for CRRT for 30 years in Japan and South Korea.
Talphera Inc (TLPH) has expressed confidence in the commercial potential of Nafamostat, citing a clear unmet need for an alternative anticoagulant in CRRT.

Negative

The initial activation and enrollment rates at clinical trial sites have not met Talphera Inc (TLPH)'s timing expectations, leading to adjustments in their strategy.
The company anticipates needing additional capital before the completion of the Nephro study, indicating potential financial constraints.
There is a risk of patient exclusion in the trial due to current safety requirements, which may not reflect the real-world application of the product.
Some clinical trial sites have been slow to meet projected enrollment numbers, which could delay the study's completion.
Talphera Inc (TLPH) faces commercial risks due to the disadvantages of current anticoagulants used during CRRT, despite their belief in Nafamostat's potential.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLPH.OQ - Talphera Inc
Q3 2024 Talphera Inc Earnings Call
Nov 13, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Okay, welcome to the Toa third quarter, 2024 financial results conference call. This call is being webcast live by via the events page of the investors section of Toa website at www dot toa dotcom.

You may listen to a replay of this webcast by going to the investors section of Tori website.

I would now like to turn the call over to Rafi Asadorian Toe's Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you for joining us on the call. Today. Today we announced our third quarter, 2024 financial results and associated business updates

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.